Insmed, Inc.
(NASDAQ : INSM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.53%303.961.4%$589.90m
AMGNAmgen, Inc.
0.46%234.481.3%$520.29m
GILDGilead Sciences, Inc.
2.41%67.521.0%$372.37m
REGNRegeneron Pharmaceuticals, Inc.
1.35%373.322.6%$304.55m
VRTXVertex Pharmaceuticals, Inc.
0.22%223.561.9%$268.71m
ILMNIllumina, Inc.
2.12%326.603.5%$238.04m
ARWRArrowhead Pharmaceuticals, Inc.
2.21%66.9812.0%$191.35m
EXASEXACT Sciences Corp.
3.22%86.3024.0%$184.18m
ALXNAlexion Pharmaceuticals, Inc.
6.75%114.682.0%$181.63m
CLVSClovis Oncology, Inc.
9.37%9.6914.7%$177.31m
SRPTSarepta Therapeutics, Inc.
-0.78%109.1014.6%$147.66m
AAgilent Technologies, Inc.
0.87%82.241.6%$141.71m
BMRNBioMarin Pharmaceutical, Inc.
0.70%80.644.3%$131.01m
SGENSeattle Genetics, Inc.
0.31%117.536.1%$128.29m
NBIXNeurocrine Biosciences, Inc.
-0.36%116.075.0%$127.11m

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.